For Chinese translation click here
点击此处查看中文翻译
Leading Scottish life sciences firm TauRx Therapeutics Management Ltd. today hailed the influence of patient advocacy groups on the Alzheimer’s disease community after bringing together top organisations from across the UK and beyond at a summit in London.
The meeting, which outlined the impact TauRx’s potential oral treatment for Alzheimer’s disease could have, helped agree shared priorities for improving outcomes for those living with Alzheimer's, as well as patient access and the challenge of ensuring innovation reaches those who could benefit.
The Aberdeen-based company is currently awaiting the outcome of a marketing authorisation application to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in relation to its lead drug, an oral tablet which could target early Alzheimer’s disease.
Senior figures from TauRx welcomed representatives from groups including Alzheimer Europe, Alzheimer Scotland and Alzheimer's Disease International to Scotland House in London to discuss the Alzheimer’s treatment landscape.
Professor Claude Wischik, TauRx Co-Founder and Chairman, said: “We are grateful for everyone sharing their time to discuss this important topic. The opportunity to gather leading patient advocacy groups in one place is rare, and it is an excellent illustration of the dedication that exists in trying to solve the global healthcare crisis that is Alzheimer’s disease.
“The conversation around our potential oral treatment was robust, as it should be, given the potential impact we believe it could have. Everyone present is working towards fulfilling the hope of slowing the decline of those impacted by Alzheimer’s.”
The groups present at Monday’s event represent the interests of people affected by Alzheimer’s and other dementias and serve as key bridge between patients, caregivers, healthcare providers, researchers, policymakers and industry.
Dr Glenn Corr, TauRx’s Chief Operations Officer and Chief Business Officer, added: “Improving outcomes for people living with Alzheimer's will require collaboration across all sectors. This excellent meeting was a real opportunity for us to do just that, and we are committed to continuing to work with all stakeholders.
“The importance of patient advocacy groups like those who joined us in London cannot be understated. For many people affected by dementia, these groups are the first place they turn to for guidance, and they do a wonderful and compassionate job assisting those who seek their help.
“We are committed to facilitating ongoing dialogue across the Alzheimer's community to help shape a future where scientific progress can be translated into real-world patient benefit.”
Peer-reviewed publications report that TauRx’s existing drug targeting the tau protein – a key hallmark of Alzheimer’s disease – halted progression of neurodegeneration, and that participants with Mild Cognitive Impairment (MCI) who received 16 mg/day experienced statistically significant cognitive improvement over 18 months.
Participants also displayed no evidence of statistically significant cognitive or functional decline over a period of two years. Trials also confirmed the drug has a benign safety profile, with headache (1.5%) and diarrhoea (1.2%) reported as the most frequent adverse effects at the 16 mg/day dose.
A decision on the company’s MHRA application is expected this year.
TauRx举办英国领先患者倡导组织阿尔茨海默病圆桌会议
苏格兰领先的生命科学公司 TauRx Therapeutics Management Ltd. 今日重申患者倡导组织在支持阿尔茨海默病患者及其照护者方面发挥的重要作用。该公司近日在伦敦举行峰会，邀请来自英国各地及其他地区的顶尖组织与会。
此次会议探讨了 TauRx在研口服阿尔茨海默病治疗药物可能带来的影响，并就改善阿尔茨海默病患者预后、提升患者可及性，以及确保创新成果惠及潜在受益人群这一挑战达成了共同优先事项。
这家总部位于阿伯丁的公司目前正等待英国药品和保健产品管理局（MHRA）对其上市许可申请作出结果。该申请涉及其核心药物，一种有望针对早期阿尔茨海默病的口服片剂。
TauRx 高层在伦敦的 Scotland House 接待了包括 Alzheimer Europe、Alzheimer Scotland 和 Alzheimer's Disease International 在内的组织代表，共同讨论阿尔茨海默病治疗格局。
TauRx 联合创始人兼董事长 Claude Wischik 教授表示：“我们感谢各位拨冗参与这一重要议题的讨论。能够将领先的患者倡导组织汇聚一堂实属难得，这也充分体现了各方在努力解决阿尔茨海默病这一全球医疗危机方面所投入的坚定承诺。
“围绕我们潜在口服疗法的讨论十分深入，这本就应当如此，因为我们相信它可能带来重大影响。与会各方都在朝着同一个希望努力，那就是减缓阿尔茨海默病患者病情恶化的进程。”
出席周一活动的这些组织代表了阿尔茨海默病及其他痴呆症受影响人群的利益，是患者、照护者、医疗服务提供者、研究人员、政策制定者与产业之间的重要桥梁。
TauRx 首席运营官兼首席商务官 Glenn Corr 博士补充道：“改善阿尔茨海默病患者的预后，需要各个领域协同合作。这次高质量会议为我们提供了切实推动合作的机会，我们也承诺将继续与所有利益相关方开展合作。
“像此次在伦敦与我们会面的患者倡导组织，其重要性怎么强调都不为过。对于许多受痴呆症影响的人而言，这些组织是他们寻求指导时首先想到的地方；在帮助求助者方面，他们展现了卓越而富有同情心的工作。
“我们致力于推动阿尔茨海默病群体内部持续对话，帮助塑造一个能够将科学进展转化为真实患者获益的未来。”
经同行评议的论文报告称，TauRx 现有的靶向 tau 蛋白的药物（tau 蛋白是阿尔茨海默病的关键标志之一）可阻止神经退行性变进展；同时，接受 16 mg/天剂量治疗的轻度认知障碍（MCI）受试者在 18 个月内出现了具有统计学意义的认知改善。
受试者在长达两年的时间里也未显示出具有统计学意义的认知或功能下降证据。试验还证实，该药物具有良好的安全性特征；在 16 mg/天剂量下，最常报告的不良反应为头痛（1.5%）和腹泻（1.2%）。
预计该公司针对 MHRA 提交的申请将于今年获得审议结果。
